The Taxane Limbo: How Low Can We Go?

The article comments on studies on the use of taxanes to treat breast cancer and other solid tumors, including a study by M. Martin and colleagues on the use of adjuvant docetaxel for node-positive breast cancer. Martin's team compared the effectiveness of an anthracycline-containing regimen against a sequence of fluorouracil, epirubicin and cyclophoshphamide (FEC). The effects of the uses of paclitaxel and docetaxel are also discussed.